Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 2Phase NA 1Phase 3 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Neoplasm Metastasis 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Hematologic Neoplasms 1Breast Neoplasms 1Advanced Cancer 1

Interventions

Cytarabine 146Azacitidine 99venetoclax 95Cyclophosphamide 70fludarabine 69Decitabine 63fludarabine phosphate 55Specimen Handling 35Filgrastim 35Daunorubicin 34Mitoxantrone 30Idarubicin 29Etoposide 27Injections 25Granulocyte Colony-Stimulating Factor 25Biopsy 24Busulfan 22Tacrolimus 21Clofarabine 21Mycophenolic Acid 18Melphalan 18Methotrexate 17Bortezomib 17Whole-Body Irradiation 16Stem Cell Transplantation 16Peripheral Blood Stem Cell Transplantation 16Vorinostat 15Gemtuzumab 15Lenalidomide 14decitabine and cedazuridine drug combination 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myeloid, Acute × Liposomes × Clear all
NCT04915612 2026-05-20

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
1 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

Thomas Jefferson University

Phase 1 Recruiting
24 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡